Sickle Cell Disease

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 | PHASE 2 | INTERVENTIONAL

This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD.

Trial Information
26 Sites
70 Participants
RECRUITING
12 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
Univ. of California, San Francisco Health Care
Oakland,California,United States,94609
University of California Irvine
Orange,California,United States,92868
Golisano Children's Hospital
Fort Myers,Florida,United States,33908
The Foundation for Sickle Cell Disease
Hollywood,Florida,United States,33023
Arthur M. Blank HospitalChildren's Healthcare of Atlanta
Atlanta,Georgia,United States,30329
University of Illinois at Chicago
Chicago,Illinois,United States,60612
University of Louisville Hospital
Louisville,Kentucky,United States,40202
University of Maryland
Baltimore,Maryland,United States,21201
Detroit Medical Center
Detroit,Michigan,United States,48201
Henry Ford Health System
Detroit,Michigan,United States,48202
St. Louis Children's Hospital
St Louis,Missouri,United States,63110
Mount Sinai Medical Center
New York,New York,United States,10029
Jacobi Medical Center
The Bronx,New York,United States,10461
East Carolina University
Greenville,North Carolina,United States,27834
University of Cincinnati
Cincinnati,Ohio,United States,45267
The Ohio State University
Columbus,Ohio,United States,43085
University of Pittsburgh
Pittsburgh,Pennsylvania,United States,15224
Hillman Cancer Center
Pittsburgh,Pennsylvania,United States,15232
Virginia Commonwealth University
Richmond,Virginia,United States,23298
Baskent University School of Medicine
Adana,Virginia,Turkey (Türkiye),01120
Hacettepe Universitesi
Ankara,Virginia,Turkey (Türkiye),06230
Istanbul Universitesi
Istanbul,Virginia,Turkey (Türkiye),34093
Medical Park Mersin Hospital
Mezitli-Mersin,Virginia,Turkey (Türkiye),33200
zel Acibadem Adana Hastanesi
Seyhan,Virginia,Turkey (Türkiye),01130
zel Acibadem Adana Hastanesi
Seyhan/Adana,Virginia,Turkey (Türkiye),01130
Guy's Hospital
London,Virginia,United Kingdom,SE19RT

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov